Transition quarter soft on revenue, strong margins; ramp-up credible but unproven

Call confirms ₹80.53 Cr value-added revenue, 30.3% YoY growth, 39.8% margin (1,477 bps expansion)

Delivered ₹202.1 Cr vs. prior-year ~₹246 Cr; trading fell to 3.3% vs. 19.5% prior year

Delivered ₹30.98 Cr EBITDA, 15.3% margin (540 bps expansion) confirmed

Q1 increase of ~5,500 tons (8% growth), but well below prior year expansion expectations

Quantified forward guidance; represents ~50% growth, not the prior 'potentially doubling' rhetoric

Prior: 'potentially doubling' (aspirational). Now: 400k+ tons for FY27 (~50% vs. FY26's 265k). Realistic for transition year but miss vs. prior rhetoric

Prior guidance: 20–25%. Current Q1 delivery: 39.8% of value-added margin but only 80.5/202 = ~40% of revenue. FY27 target now 20–22% (lower bound of prior range)

FY27 net interest cost ₹39–40 Cr (vs. FY26 ~₹7.9 Cr Q1 quarterly run-rate); Bihar subvention caps effective borrowing cost

Prior: expansion phase (₹664 Cr project, ₹552 Cr spent by Jun 30). New: 'we want to consolidate and stabilize this...then start thinking' for next expansion

Exports rose from 4.9% to 10.4% YoY; management targeting South, West, and new geographies for value-added products

Plant started Jun 1–2 (commissioned May 26). Utilization increasing, aiming for maximum within year. Q2 expected ~100–110k tons (vs. Q1's 69.7k)

Q1 added 5,500 tons split between liquid glucose (~4,500 estimate) and maltodextrin (small). FY27 value-added target 20–22% of revenue (vs. 3% in FY26)

Majorly operating leverage. Trading activity fell from 19% to 3% of turnover; manufacturing margins much higher. Raw material cost neutral year-on-year

Never faced selling challenge in past. Exports up 5%→10%, opening South/West markets. Expanded liquid glucose capacity 180→825 TPD prior, sold all. Not a concern

Cannot guide in transition phase. EBITDA per ton function of commodity prices + mix + leverage. Will improve with value-add but cannot quantify pre-commodity visibility

CFO: ₹39–40 Cr for FY27 (i.e., ~₹9.75–10 Cr/Q), flat vs. FY26 on subvention benefits. All capex debt qualifies for interest subvention

Too early to discuss next expansion. Stabilizing current one. No formal guidance on future capex or geography

Q1 up 5,500 tons (8%), 64.7k→69.7k. Old plant volumes held; new 5,500 all new contribution. Q2 expect 100–110k tons if no issues

Conversion rate (maize-to-starch) better in FY27 vs. FY26. Specific % price change not calculated; will follow up via IR team

Exports 10% now (vs. 5% prior). Opening new geographies, attending trade fairs. No specific target given; volume-dependent

Possibility is feed plant, but that's a different line. Not explored yet on margin/value-add. No concrete plan

80% of FY27 inventory procured Rabi (Apr–Jul); 10–15% from other states (Maharashtra, MP, Karnataka). Exploring Kharif crop in Bihar (~6 lakh tons, new). Inventory seasonal; should normalize as utilization ramps

Bihar/Karnataka maize best: 280–290 grams per 100 grains vs. 350–400 elsewhere. Direct farmer procurement (no logistics). Bihar low inherent consumption, so Regaal gets bulk at cheaper rates. Quality premium

EBITDA margin will improve, but combination of commodity prices (uncontrollable), mix (ramping), and leverage (scaling). Inventory priced to be competitive with Kharif (Nov–Jan). Specific margin wait until year of experience

At doorstep getting ₹22.5–23/kg, good quality. Maize prices seasonally higher Sep, soften Oct. Holding substantial stock for year; if prices rise, starch prices rise, offsetting impact. Not a concern

Indian maize prices low vs. Ukraine/USA. Starch exports globally very competitive. Even at ₹24–25/kg, Indian exports competitive per industry association calc

Already peaking, will be in H1 balance sheet. Working capital highest H1 (seasonal maize purchase). H2 debt will decline ~40% (e.g., ₹100 Cr debt→₹40 Cr by Q4)

No. Want to stabilize current expansion, get to 90–95% utilization, improve results, decrease debt first. Then think about next capex

Integration shutdowns: 9 days × ~800 TPD = ~7,200 tons lost. Liquid glucose at 70% capacity (ramp-up continuing). Maltodextrin 2–3 months to target. Q2 expected ~100–110k tons

Dextrose light of day by Q4. Maltodextrin higher margin & value-add but lower volume (50 vs. 200 tons/day liquid glucose). Modified starch portfolio online by Sep, very high margin. Mixed basis, 100% value-add to 35–40%

Capacity designed 50:50 starch/value-add. From guidance perspective, take 35% confidence. Automatically 30–35% turnover. FY27 ~20% expected (this year will be difficult to gauge)

Starch manufacturing: whole-number trade, not percentage-wise. If maize up, starch up; if down, down. EBITDA stays relatively constant if prices move together. Won't see % leverage on gross basis

Products made immediately, capacity online by Sep. 80–90% flowing to current channels (dealers, institutions, paper mills, food industry). New channels (batteries, oil drilling) ~20–30% upside. Big MNC customers acquired for liquid glucose (direct billing). Investments capitalized with main project

Completely on. Base increased, new customers added. India White brand live, existing customers increasing orders. Cross-selling and new customer additions both happening

Margins function of 3 variables: commodity prices (uncontrollable), value-add % (increasing), scale (improving). Cannot give firm guidance on % EBITDA margin. At same price levels, will do better due to leverage & value-add

Detailed data not ready; will be available from IR team on request

Represents ~50% growth; Q2 100–110k expected. 'Realistic for transition phase' tone; not the prior 'potentially doubling' rhetoric

Q1 actual 39.8% value-added margin but only ~40% of total revenue. FY27 20–22% is ramp phase; FY28 30–35% anchored on capacity 50:50 split

Management disciplined on refusal; at same price levels, will improve vs. Q1 on value-add & leverage. Maize prices ₹22.5–24/kg; starch prices move in tandem

Management explicitly deferring next capex decision until current expansion stabilizes and debt reduces. No geographic expansion planned near-term

Q1 utilization 71.4% post-commissioning (9-day integration loss ~7,200 tons). If Q2–Q3 ramp stalls, volume targets (400k+ tons FY27, 100–110k Q2) miss, and operating leverage disappears.

Liquid glucose 70% capacity; maltodextrin 2–3 months to ramp. Dextrose Anhydrous/Monohydrate not live until Q4. Modified starch trials online by Sep. Customer acceptance and pricing power on new products unproven.

Maize prices ₹22.5–24/kg (seasonal Sep spike). EBITDA per ton is 'whole-number trade'—if maize +₹1, starch +₹1 (offsetting), EBITDA flat. At ₹26–27/kg (last year peak), industry struggled. Current guidance unquantified because of commodity exposure.

Net debt ₹735 Cr (peaked H1) from ₹664 Cr capex project. Deleveraging depends on utilization ramp and margin expansion. If ramp stalls or commodity prices soften, debt service/covenant risk rises.

Gujarat Ambuja and Sanstar adding specialty starch capacity (mentioned by analyst). Pricing power on new modified starch products unproven. Management claims no past challenge selling, but value-added is new category for Regaal.

Cash conversion cycle 130 days, driven by high inventory (208 days) to support 1,650 TPD capacity. Seasonal Q1–Q2 maize procurement exacerbated this year. Tight working capital delays cash generation.